Pharmacology for Nurses Unit 20 Review: Anticoagulants and Antiplatelets in Nursing

What's the Deal with Blood Clotting?

• Blood clotting is a normal physiological process that helps stop bleeding and promote healing when blood vessels are injured
• Involves a complex cascade of events involving platelets, clotting factors, and other proteins in the blood
• Platelets are small, disc-shaped cells that play a crucial role in the initial stages of clot formation by adhering to the damaged blood vessel wall and releasing chemicals that attract more platelets
• Clotting factors are proteins in the blood that work together in a series of reactions to form fibrin, a protein that forms a mesh-like structure to stabilize the platelet plug
• The clotting cascade consists of two pathways: the intrinsic pathway (activated by factors within the blood) and the extrinsic pathway (activated by factors outside the blood, such as tissue damage)
• Both pathways converge on a common pathway that leads to the formation of thrombin, an enzyme that converts fibrinogen to fibrin
• Excessive or inappropriate clotting can lead to serious health problems, such as deep vein thrombosis (DVT), pulmonary embolism (PE), heart attack, and stroke

Anticoagulants: The Basics

• Anticoagulants are medications that prevent or slow down the clotting process by interfering with the action of clotting factors
• Used to treat and prevent blood clots in various conditions, such as atrial fibrillation, mechanical heart valves, and venous thromboembolism (VTE)
• Work by inhibiting the production or function of specific clotting factors in the coagulation cascade
• Can be administered orally (warfarin, direct oral anticoagulants) or parenterally (heparin, low-molecular-weight heparins)
• Require careful monitoring and dose adjustments to maintain therapeutic levels and minimize the risk of bleeding complications
• Patients on anticoagulants should be educated about the importance of taking the medication as prescribed, monitoring for signs of bleeding, and reporting any adverse effects to their healthcare provider
• Anticoagulants can interact with other medications, supplements, and foods, so patients should inform their healthcare provider about all the substances they are taking

Popular Anticoagulant Meds

• Warfarin (Coumadin): an oral vitamin K antagonist that inhibits the production of vitamin K-dependent clotting factors (II, VII, IX, and X)
  • Requires regular monitoring of the international normalized ratio (INR) to ensure therapeutic levels and adjust dosage
  • Interacts with many medications and foods, particularly those high in vitamin K (green leafy vegetables, liver)
• Heparin: a parenteral anticoagulant that enhances the activity of antithrombin, a natural anticoagulant that inhibits thrombin and factor Xa
  • Used for rapid anticoagulation in acute situations, such as during surgery or in patients with acute VTE
  • Administered intravenously or subcutaneously and requires close monitoring of the activated partial thromboplastin time (aPTT)
• Low-molecular-weight heparins (LMWH): derivatives of heparin with a more predictable anticoagulant effect and longer half-life (enoxaparin, dalteparin)
  • Used for prophylaxis and treatment of VTE, and in patients with acute coronary syndrome
  • Administered subcutaneously once or twice daily and do not require routine monitoring of coagulation parameters
• Direct oral anticoagulants (DOACs): newer agents that directly inhibit specific clotting factors, such as thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban, edoxaban)
  • Have a rapid onset of action, predictable anticoagulant effect, and fewer drug interactions compared to warfarin
  • Do not require routine monitoring of coagulation parameters, but may need to be held or reversed in certain situations (surgery, bleeding)

Antiplatelets: How They're Different

• Antiplatelets are medications that prevent platelets from sticking together and forming clots
• Work by inhibiting the production or action of substances that promote platelet aggregation, such as thromboxane A2 and adenosine diphosphate (ADP)
• Used to prevent arterial thrombosis in conditions such as coronary artery disease, peripheral artery disease, and cerebrovascular disease
• Do not affect the coagulation cascade or the formation of fibrin, unlike anticoagulants
• Generally have a lower risk of bleeding compared to anticoagulants, but can still cause significant bleeding, especially when used in combination with other antiplatelets or anticoagulants
• Patients on antiplatelets should be monitored for signs of bleeding and educated about the importance of taking the medication as prescribed and reporting any adverse effects to their healthcare provider
• Some antiplatelets, such as aspirin, can also have additional effects, such as reducing inflammation and preventing colorectal cancer

Common Antiplatelet Drugs

• Aspirin: an irreversible inhibitor of cyclooxygenase-1 (COX-1), an enzyme that produces thromboxane A2, a potent platelet activator
  • Used for primary and secondary prevention of cardiovascular events, such as myocardial infarction and stroke
  • Administered orally at low doses (81-325 mg) once daily
  • Can cause gastrointestinal side effects, such as dyspepsia and ulcers, and increase the risk of bleeding
• Clopidogrel (Plavix): an irreversible inhibitor of the P2Y12 receptor, which prevents ADP-induced platelet aggregation
  • Used for secondary prevention of cardiovascular events, particularly in patients with acute coronary syndrome or undergoing percutaneous coronary intervention (PCI)
  • Administered orally at a dose of 75 mg once daily, with a loading dose of 300-600 mg in acute situations
  • Requires hepatic activation by the CYP2C19 enzyme, which can be affected by genetic variations and drug interactions
• Prasugrel (Effient) and ticagrelor (Brilinta): newer P2Y12 inhibitors with faster onset of action and more potent antiplatelet effects compared to clopidogrel
  • Used for secondary prevention of cardiovascular events in patients with acute coronary syndrome or undergoing PCI
  • Administered orally at a dose of 10 mg once daily for prasugrel and 90 mg twice daily for ticagrelor, with a loading dose of 60 mg for prasugrel and 180 mg for ticagrelor
  • Have a higher risk of bleeding compared to clopidogrel, but are less affected by genetic variations and drug interactions

Nursing Considerations and Patient Teaching

• Assess patients for contraindications and risk factors for bleeding before starting anticoagulant or antiplatelet therapy
  • Contraindications may include active bleeding, recent surgery or trauma, severe liver or kidney disease, and uncontrolled hypertension
  • Risk factors for bleeding include older age, history of bleeding or stroke, concomitant use of other medications that increase bleeding risk (NSAIDs, SSRIs), and alcohol abuse
• Educate patients about the purpose, dosage, and administration of their anticoagulant or antiplatelet medication
  • Emphasize the importance of taking the medication as prescribed and not stopping it without consulting their healthcare provider
  • Instruct patients on how to handle missed doses and what to do in case of bleeding or other adverse effects
• Monitor patients for signs and symptoms of bleeding, such as easy bruising, prolonged bleeding from cuts, nosebleeds, heavy menstrual bleeding, and dark or bloody urine or stools
  • Teach patients to report any unusual bleeding or severe headache, dizziness, or weakness to their healthcare provider immediately
• Advise patients to inform all their healthcare providers, including dentists and pharmacists, about their anticoagulant or antiplatelet therapy
  • Patients should carry a medication card or wear a medical alert bracelet indicating their use of these medications
• Counsel patients on lifestyle modifications that can help reduce the risk of thrombosis and bleeding
  • Encourage regular exercise, healthy diet, smoking cessation, and limiting alcohol intake
  • Advise patients to avoid activities with a high risk of injury or bleeding, such as contact sports or using sharp objects
• Provide patients with written information and resources about their anticoagulant or antiplatelet therapy, and encourage them to ask questions and voice any concerns they may have

Side Effects and Complications to Watch For

• Bleeding is the most common and serious side effect of anticoagulant and antiplatelet therapy
  • Can range from minor bruising and nosebleeds to life-threatening intracranial or gastrointestinal hemorrhage
  • Risk of bleeding increases with higher doses, longer duration of therapy, and concomitant use of other medications that affect hemostasis
• Heparin-induced thrombocytopenia (HIT) is a rare but serious complication of heparin therapy
  • Occurs when antibodies against heparin-platelet factor 4 complexes cause platelet activation and consumption, leading to thrombocytopenia and paradoxical thrombosis
  • Typically develops 5-14 days after starting heparin therapy and requires immediate discontinuation of heparin and initiation of alternative anticoagulation
• Warfarin can cause skin necrosis, a rare but severe complication that occurs in the first few days of therapy
  • Characterized by painful, purpuric lesions that progress to bullae and necrosis, usually in areas with more subcutaneous fat (breasts, thighs, buttocks)
  • Thought to be caused by a transient hypercoagulable state due to the rapid depletion of protein C, a natural anticoagulant
• Other side effects of anticoagulants and antiplatelets may include:
  • Gastrointestinal symptoms, such as dyspepsia, nausea, and diarrhea
  • Headache, dizziness, and fatigue
  • Allergic reactions, such as rash, pruritus, and anaphylaxis (rare)
• Patients should be instructed to report any unusual symptoms or side effects to their healthcare provider promptly

Lab Tests and Monitoring

• Patients on anticoagulant and antiplatelet therapy require regular laboratory monitoring to ensure therapeutic efficacy and minimize the risk of bleeding complications
• For warfarin, the international normalized ratio (INR) is used to monitor the anticoagulant effect
  • The INR is a standardized measure of the prothrombin time (PT), which reflects the activity of vitamin K-dependent clotting factors
  • The target INR range for most indications is 2.0-3.0, but may be higher for certain conditions, such as mechanical heart valves
  • INR should be monitored at least weekly during initiation of therapy, and every 2-4 weeks once stable
• For heparin, the activated partial thromboplastin time (aPTT) is used to monitor the anticoagulant effect
  • The aPTT is a measure of the intrinsic and common pathways of the coagulation cascade
  • The target aPTT range varies depending on the indication and the specific heparin protocol used, but is typically 1.5-2.5 times the upper limit of normal
  • aPTT should be monitored every 6 hours during continuous infusion, and 6 hours after each dose adjustment
• For low-molecular-weight heparins and direct oral anticoagulants, routine monitoring of coagulation parameters is not necessary in most patients
  • However, in certain situations, such as renal impairment, extremes of body weight, or bleeding complications, measuring drug-specific anti-factor Xa levels or dilute thrombin time may be useful
• For antiplatelets, there is no widely accepted laboratory test for monitoring the antiplatelet effect
  • Platelet function tests, such as platelet aggregometry or platelet function analyzers, may be used in certain situations, such as assessing the response to clopidogrel or evaluating the risk of bleeding before surgery
• Other laboratory tests that may be used to monitor patients on anticoagulant or antiplatelet therapy include:
  • Complete blood count (CBC) to monitor for anemia and thrombocytopenia
  • Renal function tests (creatinine, eGFR) to adjust dosage of certain medications and monitor for bleeding risk
  • Liver function tests (ALT, AST, bilirubin) to monitor for hepatotoxicity and adjust dosage of certain medications